Most common adverse reactions
AZD4635 with AZD4635 with
durvalumab oleclumab
Adverse reaction (out of 29 participants) (out of 30 participants)
Nausea 37.9% (11) 53.3% (16)
Feeling tired 20.7% (6) 30.0% (9)
Decreased appetite 17.2% (5) 16.7% (5)
Vomiting 10.3% (3) 23.3% (7)
Diarrhea 13.8% (4) 10.0% (3)
Feeling dizzy 13.8% (4) 6.7% (2)
Constipation 10.3% (3) 3.3% (1)
Low amount of a type of blood cell called platelets, 0.0% (0) 6.7% (2)
which help blood to clot
Difficulty sleeping 6.9% (2) 0.0% (0)
High blood pressure 0.0% (0) 6.7% (2)
Pain in the stomach 6.9% (2) 0.0% (0)
Disease where stomach acid often goes upwards 3.4% (1) 3.3% (1)
into the tube connecting the mouth and stomach
Itching 3.4% (1) 3.3% (1)
Rash 3.4% (1) 3.3% (1)
Swelling of lower legs or hands 6.9% (2) 0.0% (0)
Increased amounts in the blood of a type of protein 3.4% (1) 3.3% (1)
called amylase that helps digest food
How has this study helped patients and
researchers?
This study helped researchers learn more about how AZD4635 with durvalumab or
with oleclumab worked in participants with prostate cancer.
Researchers look at the results of many studies to decide which treatments work
best and are safest. This summary shows only the main results from this one study.
Other studies may provide new information or different results.
Further clinical studies with AZD4635 with durvalumab and with oleclumab are not
planned by the sponsor at this time.
11 | Clinical Study Results